STAT+: Abivax seeks to ease safety concerns with new data, boosting shares

STAT PlusBiotech Abivax seeks to ease safety concerns with new data, boosting shares The company released additional strong efficacy results, in a group of hard-to-treat patients Manage alerts for this article Email this article Share this article By Andrew JosephJune 30, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks. U.S.-listed shares of the French firm were up some 25% overnight into Tuesday morning. Advertisement Earlier this month, Abivax reported that the drug, called obefazimod, delivered strong efficacy in a closely watched maintenance trial, with far more participants on the study drug entering a period of no symptoms of their bowel disease versus those on placebo. But a number of cancer cases among people on obefazimod raised questions about potential safety risks, with company shares plummeting in response. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, chronic disease, drug development, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Exclusive June 29, 2026 STAT Plus: FDA’s top gene therapy regulator is leaving his role The Readout June 29, 2026 STAT Plus: Talawar bets bispecific approach can shake up eczema market Advertisement Biotech June 29, 2026 STAT Plus: Investor Clive Meanwell on designing biotechs for population health, and AI’s role as a catalyst Biotech June 29, 2026 STAT Plus: Moderna co-founder Kenneth Chien on the future of mRNA — and Moderna Opinions+ June 29, 2026 STAT Plus: The U.S.-China biotech crackdown may hurt the scientists America needs the most Subscriber Picks